{"DataElement":{"publicId":"3438620","version":"2","preferredName":"Therapeutic Procedure Monoclonal Antibody Performed COG Monoclonal Antibody Type","preferredDefinition":"Monoclonal antibody or other agent administered as prior anti-cancer therapy with a known half life._Type of Monoclonal antibody or other agent received by the patient","longName":"MonoclonalAntibody","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"3438603","version":"1","preferredName":"Therapeutic Procedure Monoclonal Antibody Performed","preferredDefinition":"Monoclonal antibody or other agent administered as prior anti-cancer therapy with a known half life.","longName":"2512834v1.0:3438601v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3438601","version":"1","preferredName":"Monoclonal Antibody Performed","preferredDefinition":"An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:Performed; carried out.","longName":"C20401:C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF9ACA1-534D-F817-E040-BB89AD431CF1","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF9ACA1-535E-F817-E040-BB89AD431CF1","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3438591","version":"1","preferredName":"COG Monoclonal Antibody Type","preferredDefinition":"Type of Monoclonal antibody or other agent received by the patient","longName":"3438591v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"55","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other Specify","valueDescription":"OTHER THERAPY","ValueMeaning":{"publicId":"2563822","version":"1","preferredName":"OTHER THERAPY","longName":"2563822","preferredDefinition":"OTHER THERAPY","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other Therapy","conceptCode":"C15645","definition":"Definition not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C65B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-23","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3DD4-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"GDC-0449","valueDescription":"Vismodegib","ValueMeaning":{"publicId":"3438593","version":"1","preferredName":"Vismodegib","longName":"3438593","preferredDefinition":"An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vismodegib","conceptCode":"C74038","definition":"An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3DE1-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3DFA-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"SGN-35","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E0E-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"SGN-30","valueDescription":"Monoclonal Antibody SGN-30","ValueMeaning":{"publicId":"3438595","version":"1","preferredName":"Monoclonal Antibody SGN-30","longName":"3438595","preferredDefinition":"A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab","conceptCode":"C2007","definition":"A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3E1B-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E34-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Nimotuzimab","valueDescription":"Nimotuzimab","ValueMeaning":{"publicId":"3438596","version":"1","preferredName":"Nimotuzimab","longName":"3438596","preferredDefinition":"Nimotuzimab","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3E3E-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E57-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"2738482","version":"1","preferredName":"Rituximab","longName":"2738482","preferredDefinition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F890-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E61-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"IMC-A12","valueDescription":"Cixutumumab","ValueMeaning":{"publicId":"3379110","version":"1","preferredName":"Cixutumumab","longName":"3379110","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cixutumumab","conceptCode":"C79828","definition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-ABC8-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E6B-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Gemtuzumab","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E75-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Epratuzumab","valueDescription":"Epratuzumab","ValueMeaning":{"publicId":"3438598","version":"1","preferredName":"Epratuzumab","longName":"3438598","preferredDefinition":"A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epratuzumab","conceptCode":"C1887","definition":"A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.  After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3E82-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3E9B-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3EA5-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Ch 14.18","valueDescription":"Ch 14.18","ValueMeaning":{"publicId":"3438599","version":"1","preferredName":"Ch 14.18","longName":"3438599","preferredDefinition":"Ch 14.18","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3EAF-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3EC8-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3ED2-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BDF86B4A-3EDC-584B-E040-BB89AD43471A","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EB9A-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Ramucirumab","valueDescription":"Ramucirumab","ValueMeaning":{"publicId":"3553252","version":"1","preferredName":"Ramucirumab","longName":"3553252","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ramucirumab","conceptCode":"C70792","definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6BB9C1D-7980-2974-E040-BB89AD430E5E","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EB77-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Ontuxizumab","valueDescription":"Anti-Endosialin Monoclonal Antibody MORAb-004","ValueMeaning":{"publicId":"3614158","version":"1","preferredName":"Anti-Endosialin Monoclonal Antibody MORAb-004","longName":"3614158","preferredDefinition":"A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Anti-endosialin/TEM1 monoclonal antibody MORAb-004 binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ontuxizumab","conceptCode":"C82406","definition":"A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Ontuxizumab binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CC30A674-8DC4-B756-E040-BB89AD4314E4","latestVersionIndicator":"Yes","beginDate":"2012-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EBAE-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EBD1-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Lorvotuzumab","valueDescription":"Lorvotuzumab Mertansine","ValueMeaning":{"publicId":"5076696","version":"1","preferredName":"Lorvotuzumab Mertansine","longName":"5076696","preferredDefinition":"An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorvotuzumab Mertansine","conceptCode":"C38714","definition":"An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBDE-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EBF7-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EC01-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"I-3F8","valueDescription":"Monoclonal Antibody 3F8","ValueMeaning":{"publicId":"5076698","version":"1","preferredName":"Monoclonal Antibody 3F8","longName":"5076698","preferredDefinition":"A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody 3F8","conceptCode":"C2370","definition":"A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EC0E-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EC27-5B33-E050-BB89AD437FF5","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Cixutumumab","valueDescription":"Cixutumumab","ValueMeaning":{"publicId":"3379110","version":"1","preferredName":"Cixutumumab","longName":"3379110","preferredDefinition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cixutumumab","conceptCode":"C79828","definition":"A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9163F61-ABC8-188C-E040-BB89AD435BED","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EC3B-5B33-E050-BB89AD437FF5","beginDate":"2012-04-18","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2653AD7D-EC45-5B33-E050-BB89AD437FF5","beginDate":"2012-04-18","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"ONEDATA","dateModified":"2015-12-07","deletedIndicator":"No"},{"value":"Complement C5 inhibitor (Eculizumab, Ravalizumab)","valueDescription":"Complement C5 inhibitor (Eculizumab, Ravalizumab)","ValueMeaning":{"publicId":"8067795","version":"1","preferredName":"Complement C5 inhibitor (Eculizumab, Ravalizumab)","longName":"8067795","preferredDefinition":"Complement C5 inhibitor (Eculizumab, Ravalizumab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D941D3CA-EE00-243B-E053-4EBD850A3752","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D941D3CA-EE19-243B-E053-4EBD850A3752","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"CD52 target (Alemtuzumab)","valueDescription":"CD52 target (Alemtuzumab)","ValueMeaning":{"publicId":"8067796","version":"1","preferredName":"CD52 target (Alemtuzumab)","longName":"8067796","preferredDefinition":"CD52 target (Alemtuzumab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D941D3CA-EE23-243B-E053-4EBD850A3752","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D941D3CA-EE3C-243B-E053-4EBD850A3752","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"CD38 target (Daratumumab)","valueDescription":"CD38 target (Daratumumab)","ValueMeaning":{"publicId":"8067797","version":"1","preferredName":"CD38 target (Daratumumab)","longName":"8067797","preferredDefinition":"CD38 target (Daratumumab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D941D3CA-EE46-243B-E053-4EBD850A3752","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D941D3CA-EE5F-243B-E053-4EBD850A3752","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"CD30 target (Brentuximab)","valueDescription":"CD30 target (Brentuximab)","ValueMeaning":{"publicId":"8067798","version":"1","preferredName":"CD30 target (Brentuximab)","longName":"8067798","preferredDefinition":"CD30 target (Brentuximab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D941D3CA-EE69-243B-E053-4EBD850A3752","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D941D3CA-EE82-243B-E053-4EBD850A3752","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)","valueDescription":"CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)","ValueMeaning":{"publicId":"8067799","version":"1","preferredName":"CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)","longName":"8067799","preferredDefinition":"CD20 target (Obinutuzumab, Ofatuzumab, Rituximab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D941D3CA-EE8C-243B-E053-4EBD850A3752","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D941D3CA-EEA5-243B-E053-4EBD850A3752","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"},{"value":"CD19 CD3 target (Blinatumomab)","valueDescription":"CD19 CD3 target (Blinatumomab)","ValueMeaning":{"publicId":"8067800","version":"1","preferredName":"CD19 CD3 target (Blinatumomab)","longName":"8067800","preferredDefinition":"CD19 CD3 target (Blinatumomab)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D941D3CA-EEAF-243B-E053-4EBD850A3752","latestVersionIndicator":"Yes","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D941D3CA-EEC8-243B-E053-4EBD850A3752","beginDate":"2022-03-02","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-02","modifiedBy":"ONEDATA","dateModified":"2022-03-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3DB5-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-04-18","modifiedBy":"COOPERJ","dateModified":"2022-03-02","changeDescription":"Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"},{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]}],"AlternateNames":[{"name":"MonoclonalAntibody","type":"USED_BY","context":"CTEP"},{"name":"MonoclonalAntibody","type":"USED_BY","context":"COG"},{"name":"MONO_ANT_TYP","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"Select the patient's most rec","type":"Preferred Question Text","description":"Select the patient's most recent monoclonal antibody received","url":null,"context":"COG"},{"name":"COG CRF text 1","type":"Alternate Question Text","description":"Monoclonal Antibody Type:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3FE65AF-7980-3C65-E040-BB89AD43608F","latestVersionIndicator":"Yes","beginDate":"2013-01-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-01-23","modifiedBy":"COOPERJ","dateModified":"2022-03-02","changeDescription":"V2 Short Name Change Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}